Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders

NCT01288716 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.

NCT NCT01288716
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01288716 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of STX209 (Arbaclofen) Administered for the Treatment of Social Withdrawal in Subjects With Autism Spectrum Disorders
Lead sponsor
Seaside Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2011
Completion date
September 30, 2012
Enrollment
150 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorders